Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is in a strong financial position, with a large market share in the US and a wide range of products and services. They have a strong focus on innovation and efficiency, and with an expanding customer base and product categories, they are poised for continued growth and success in the future. Additionally, their international expansion and higher-margin segment contribute to their potential for significant economic profit and shareholder value.

Bears say

Medline is poised for growth due to its recent automation investments, including a deal with Symbotic, that will improve operational and clinical efficiency while reducing costs. With strong organic revenue growth, margin expansion, and operating leverage, Medline is expected to benefit from its deep customer integration through the MPower ecosystem and potential software/services economics, as well as international expansion and channel diversification. An active M&A agenda, post-IPO deleveraging, and strong prime-vendor retention further support the company's premium cash-flow multiples for above-market earnings growth potential.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.